Rare Partners is a non profit company devoted to the development of new therapies and diagnostics in the field of rare diseases.

The European Commission grants Orphan Drug Designation to Neupharma for the use of Teicoplanin in Cystic Fibrosis, a program developed in collaboration with Rare Partners

RP announcement - read more

Rare Partners supports the IIT for the development of an innovative artificial retina 

RP announcement - read more

A new Orphan Drug Designation to Sirolimus

RP announcement - read more
Syndicate content